Clinical Trial Update: Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy [Phase 1]

View source ↗

Summary

A Phase 1 trial assessing safety, tolerability, and pharmacokinetics of C2N-8E12 in progressive supranuclear palsy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Supranuclear Palsy

Drugs mentioned

• C2N-8E12

Snippet

Sponsor: C2N Diagnostics | Conditions: Progressive Supranuclear Palsy | Phase 1 | Status: COMPLETED